European journal of nuclear medicine and molecular imaging · 2025
Fibroblast activation protein-targeted PET/CT with 68Ga-FAPI-46 for evaluation of structural damage and inflammation in axial spondyloarthritis: a prospective study.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Yangchun, Yu Lingyu, Chen Shiju, Liu Wen, Han Haiwei, Pang Yizhen, Lin Qingyan, Li Yan, Chen Liying, Cai Jiayu, Zhao Liang, Sun Long, Shi Guixiu, Chen Haojun, Liu Yuan
Аннотация
OBJECTIVE: Axial spondyloarthritis (axSpA) is characterized by active inflammation and structural damage. To date, there is no imaging tool can alone visualize all those changes well. PET/CT imaging with gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) provide extra ability for CT in detecting active inflammation in addition to its advantage in assessing structural damage. This study aims to explore the utility of 68Ga-FAPI-46 PET/CT for assessing active inflammation in axSpA.
METHODS: Between July 2023 to July 2024, 22 patients with axSpA and 12 healthy volunteers were prospectively enrolled. Disease activity and parameters associated with inflammation were evaluated at enrollment. Participants then underwent 68Ga-FAPI-46 PET/CT for assessment of FAPI uptake across joints. 68Ga-FAPI-46 uptake was semi-quantitatively evaluated by using a three-point scale. The sum of points was calculated to generate 68Ga-FAPI-46 PET/CT-derived FAPI uptake scores. Patients receiving biologics therapy were grouped as responders or non-responders according to clinical follow-up.
RESULTS: Compared to healthy volunteers, patients with axSpA exhibited significantly higher 68Ga-FAPI-46 uptake in several joints, especially in spine (p < 0.001). 68Ga-FAPI-46 PET/CT scores in spine showed strong correlation with the Ankylosing Spondylitis Disease Activity Score (ASDAS), inflammatory indicators such as c-reactive protein (CRP), and inflammation visualized by magnetic resonance imaging (MRI). Biologic responders displayed markedly higher baseline 68Ga-FAPI-46 PET/CT scores in the spine (median: 36.5 vs. 4.0, p = 0.017) and total joints (median: 53.5 vs. 11.0, p = 0.015) compared to non-responders.
CONCLUSION: 68Ga-FAPI-46 PET/CT has the potential to serve as a dual-function imaging tool, integrating the structural imaging capabilities of CT with the ability to detect inflammation.
CLINICAL TRIAL REGISTRATION: NCT05999643.
METHODS: Between July 2023 to July 2024, 22 patients with axSpA and 12 healthy volunteers were prospectively enrolled. Disease activity and parameters associated with inflammation were evaluated at enrollment. Participants then underwent 68Ga-FAPI-46 PET/CT for assessment of FAPI uptake across joints. 68Ga-FAPI-46 uptake was semi-quantitatively evaluated by using a three-point scale. The sum of points was calculated to generate 68Ga-FAPI-46 PET/CT-derived FAPI uptake scores. Patients receiving biologics therapy were grouped as responders or non-responders according to clinical follow-up.
RESULTS: Compared to healthy volunteers, patients with axSpA exhibited significantly higher 68Ga-FAPI-46 uptake in several joints, especially in spine (p < 0.001). 68Ga-FAPI-46 PET/CT scores in spine showed strong correlation with the Ankylosing Spondylitis Disease Activity Score (ASDAS), inflammatory indicators such as c-reactive protein (CRP), and inflammation visualized by magnetic resonance imaging (MRI). Biologic responders displayed markedly higher baseline 68Ga-FAPI-46 PET/CT scores in the spine (median: 36.5 vs. 4.0, p = 0.017) and total joints (median: 53.5 vs. 11.0, p = 0.015) compared to non-responders.
CONCLUSION: 68Ga-FAPI-46 PET/CT has the potential to serve as a dual-function imaging tool, integrating the structural imaging capabilities of CT with the ability to detect inflammation.
CLINICAL TRIAL REGISTRATION: NCT05999643.